Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02659059. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.
Study identification
- NCT ID
- NCT02659059
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 324 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Platinum Doublet Chemotherapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2016 (Actual)
- Primary completion
- Jun 22, 2018 (Actual)
- Completion
- Mar 7, 2022 (Actual)
- Last update posted
- Apr 5, 2023
2016 – 2022
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Cancer Center Of Central Connecticut | Plainville | Connecticut | 06062 | — |
| Cleveland Clinic Florida | Weston | Florida | 33331 | — |
| Winship Cancer Institute. | Atlanta | Georgia | 30322 | — |
| Summit Cancer Care | Savannah | Georgia | 31405 | — |
| Cancer Center Of Kansas | Wichita | Kansas | 67214 | — |
| University Of Louisville Medical Center, Inc., Dba | Louisville | Kentucky | 40202 | — |
| Johns Hopkins Cancer Center | Baltimore | Maryland | 21287 | — |
| Local Institution - 0029 | Boston | Massachusetts | 02114-2621 | — |
| Local Institution - 0030 | Boston | Massachusetts | 02114-2621 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Local Institution - 0015 | Lincoln | Nebraska | 68506 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0036 | Albuquerque | New Mexico | 87106 | — |
| Lovelace Cancer Care | Albuquerque | New Mexico | 87131 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87131 | — |
| New Mexico Cancer Care Center | Albuquerque | New Mexico | 87131 | — |
| The Cancer Center at Presbyterian | Albuquerque | New Mexico | 87131 | — |
| Local Institution - 0010 | Mineola | New York | 11501 | — |
| Memorial Sloan Kettering Nassau | New York | New York | 10065 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Novant Health Oncology Specialists | Winston-Salem | North Carolina | 27103 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2412 | — |
| Local Institution - 0006 | Pittsburgh | Pennsylvania | 15212 | — |
| Charleston Hematology Oncology Associates, Pa | Charleston | South Carolina | 29414 | — |
| Tennessee Oncology, PLLC - SCRI - PPDS | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6307 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02659059, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2023 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02659059 live on ClinicalTrials.gov.